Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 1929 (LINC01929)
- Target
- LINC01929
- Molecular classification
- Long non-coding RNA (lncRNA), Intergenic lncRNA, Competing endogenous RNA (ceRNA)
01
Overview
Long intergenic non-protein coding RNA 1929 (LINC01929) is a human long non-coding RNA (lncRNA) located in non-protein coding genomic regions. LINC01929 is upregulated in multiple cancer types and functions as a regulatory RNA, particularly acting as a competing endogenous RNA (ceRNA) that sequesters specific microRNAs (such as miR-1179), thereby modulating gene expression that promotes cell proliferation, metastasis, and cell cycle progression. Elevated expression of LINC01929 correlates with poor prognosis in cancers such as breast and non-small cell lung carcinoma. It is associated with tumor immune parameters, serving as both a prognostic biomarker and a potential future therapeutic target. No drugs currently target LINC01929 directly in clinical settings.
- Other names
- LINC01929long intergenic non-protein coding RNA 1929
02
Mechanism of action
Molecular sponge function for miR-1179 (negatively regulates miR-1179, impacting downstream gene expression); Modulation of TNF pathway and STAT3 signaling; General ceRNA mechanism affecting tumorigenesis
03
Biological functions
Regulation of cell proliferationPromotion of cell cycle progressionModeration of apoptosisActing as a molecular sponge for microRNAs (e.g., miR-1179)Regulation of immune cell infiltration and checkpoint expressionPotential involvement in chromatin remodeling and RNA stability
04
Disease associations
Cancer (pan-cancer biomarker and therapeutic target)Specific roles in non-small cell lung carcinomaSpecific roles in breast cancerSpecific roles in oral squamous cell carcinomaSpecific roles in hepatocellular carcinoma
05
Safety considerations
As of now, research is preclinical and does not document specific safety concerns or therapeutic challenges. RNA-based therapies may encounter issues with delivery, specificity, and off-target effects, but these are general to the modality, not the molecule itself.
06
Biomarkers
LINC01929 expression (predictive of prognosis in several cancers)Associated with tumor mutational burden (TMB)Associated with microsatellite instability (MSI)Associated with immune checkpoint status
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 1929 (LINC01929).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 1929 (LINC01929).